The leader 
in prognostic melanoma testing

Navigate your melanoma journey with confidence

What is DecisionDx-Melanoma?

DecisionDx-Melanoma is a gene expression profiling (GEP) test that looks at your tumor biology to predict the risk of your melanoma spreading or coming back. The test uses a small sample from the melanoma biopsy that your provider has already taken, so there is no need for another procedure or blood draw. 

It is the only GEP test associated with improved survival

Provides personalized information to guide treatment

We will work with all insurance providers to ensure coverage

I want to connect to a provider near me

How does the test impact your melanoma treatment?

  • Provides insights to personalize frequency of follow-up appointments with your health care provider

  • Informs decisions on additional procedures, like sentinel lymph node biopsy

  • Results impact additional visits with other specialties (referrals)

  • Can guide escalations or de-escalations of your treatment plan including advanced imaging

Backed by data. Validated in real-world practice

A recent study, conducted in collaboration with the National Cancer Institute (NCI), found that patients who used the DecisionDx-Melanoma test had better survival outcomes. The test gives doctors important information about your specific melanoma, helping them create a treatment plan that's personalized just for you. By understanding your unique risk, you and your doctor can make more informed decisions about your care. 

29% Lower 3-year melanoma-specific mortality rate in patients clinically tested vs. untested 17% Lower 3-year overall mortality rate in patients clinically tested vs. untested

More informed decisions for your care. 

By better understanding the risk of your individual tumor biology, your provider can make better management decisions. The bottom line? More personalized treatment leads to better outcomes.

Not all GEP tests are the same. DecisionDx-Melanoma is the only test that can provide you with a comprehensive test result that gives you a clinically validated, personalized risk assessment. DecisionDx-Melanoma is the only test with over 150,000 patients studied and 50 peer-reviewed publications

The value of a test is driven by the value of information it provides. DecisionDx-Melanoma has continued to show that it offers data that is above and beyond what traditional staging can provide. 

Other
GEP tests
Identifies patient risk for nodal metastasis ✔ ✔
Provides personalized risk for sentinel lymph node positivity ✔ x
Provides personalized risk of recurrence including MSS, RFS, and DMFS ✔ x
Data demonstrates independent, significant risk stratification provided by GEP result compared to AJCC stage ✔ x
Data demonstrates improved patient survival associated with testing ✔ x

DecisionDx-Melanoma is supported by over 50 peer-reviewed publications. Check out our abundance of clinical data here.

Take the next step towards personalized care

Maybe you or a loved one have been diagnosed with, or may suspect, cutaneous melanoma and you're not sure what to do next. No matter where you are in your melanoma journey, we can help you with next steps.

  • Get connected to a provider

    We can help you find a provider near you who offers the DecisionDx-Melanoma test. Fill out the form below and we will be in touch with more information.

    I want to get connected to a provider

  • Discuss the test with your current provider

    Feel empowered to discuss the possibility of this test being incorporated into your current treatment. Use the guide below to facilitate the conversation.

    I want to download the discussion guide

You are not alone. How DecisionDx-Melanoma impacted a patient's treatment journey

If you or someone you care about has been diagnosed with or suspects cutaneous melanoma, being your own advocate is crucial. Morgan England, a Stage III melanoma survivor, shares how advocating for herself led her to the DecisionDx-Melanoma test. Morgan gained critical insights into her tumor biology, which guided personalized treatment decisions and changed the course of her care.

Join our community

Many people don't know the signs of melanoma or when to see a doctor. In fact, only 37% of Americans can identify one or more risk factors of melanoma. Whether you know a lot or a little about melanoma, it's important to continue to educate yourself for the sake of your own health and your loved ones.

Sign me up for the mailing list

American Academy of Dermatology. (2017). *New survey reveals only 37% of Americans can identify a risk factor for melanoma*.